# US 2022/0378725 A1 · Composition of acylethanolamides from olive oil fatty acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0378725 A1
- Document ID: US20220378725A1
- Status: Published application
- Kind: A1
- Application number: 17/825,260
- Filed: 2022-05-26
- Published: 2022-12-01
- Earliest claimed: 2021-05-28
- Assignees: Epitech Group S.r.l.
- Applicants: Epitech Group S.P.A.
- Inventors: Francesco DELLA VALLE; Maria Federica DELLA VALLE; Gabriele MARCOLONGO; Chiara GOMIERO
- Web page: https://patentgrep.com/patent/US20220378725A1

## CPC

- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61P 3/04: Anorexiants; Antiobesity agents
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/143: {with inorganic compounds}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61P 25/00: Drugs for disorders of the nervous system
- C07C 231/02: from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- C07C 231/20: by separation of optical isomers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): oleoylethanolamide (OEA) C18:1 60-65% palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8% myristoylethanolamide (MEA) C14:0 0.02-0.15% mixture of glycerides 4-6% glycerol 6-8%. A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.

## Claims

### Claim 1

An acylethanolamide composition comprising (percentages by weight):
oleoylethanolamide (OEA) C18:1
60-65%
palmitoylethanolamide (PEA) C16:0
5-20%
linoleylethanolamide (LEA) C18:2
5-20%
stearoylethanolamide (SEA) C18:0
1-2%
palmitoleoylethanolamide (POEA) C16:1
0.1-0.8%
myristoylethanolamide (MEA) C14:0
0.02-0.15%
mixture of glycerides
4-6%
glycerol
6-8%.

### Claim 2 (depends on 1)

The acylethanolamide composition according to claim 1, comprising (percentages by weight):
oleoylethanolamide (OEA) C18:1
61-63%
palmitoylethanolamide (PEA) C16:0
17-19%
linoleylethanolamide (LEA) C18:2
5-5.7%
stearoylethanolamide (SEA) C18:0
1.2-1.7%
palmitoleoylethanolamide (POEA) C16:1
0.3-0.5%
myristoylethanolamide (MEA) C14:0
0.03-0.11%
mixture of glycerides
5-5.5%
glycerol
7-7.5%.

### Claim 3 (depends on 1)

The acylethanolamide composition according to claim 1, comprising (percentages by weight):
oleoylethanolamide (OEA) C18:1
61-63%
palmitoylethanolamide (PEA) C16:0
7-12%
linoleylethanolamide (LEA) C18:2
8-15%
stearoylethanolamide (SEA) C18:0
1.2-1.7%
palmitoleoylethanolamide (POEA) C16:1
0.3-0.5%
myristoylethanolamide (MEA) C14:0
0.03-0.11%
mixture of glycerides
5-5.5%
glycerol
7-7.5%.

### Claim 4

A method of direct uncatalyzed aminolysis in the absence of solvent from olive oil with 2-aminoethanol, comprising the following steps:
a) mixing olive oil with 2-aminoethanol;
b) heating the mixture of step a) to a temperature between 120° C. and 160° C.;
c) separating an acylethanolamide composition obtained in the form of a waxy solid;
d) optionally, absorbing the acylethanolamide composition of step c) on porous amorphous silica, thus obtaining an acylethanolamide composition/porous amorphous silica adsorption compound.

### Claim 5 (depends on 4)

The method according to claim 4, wherein in step a) the weight ratio of olive oil/2-ethanolamine is between 100:13 and 100:22.

### Claim 6 (depends on 4)

The method according to claim 4, wherein step b) is carried out at a temperature between 130° C. and 150° C., and for a time over 2 hours and less than 5 hours.

### Claim 7 (depends on 4)

The method according to claim 4, wherein step d) is carried out by melting the acylethanolamide composition of step c) at a temperature between 70° C. and 90° C. and then adding porous amorphous silica, and wherein the weight ratio of acylethanolamide composition to porous amorphous silica is between 0.9:1 and 1.1:1.

### Claim 8 (depends on 4)

An acylethanolamide composition as obtainable by the method according to claim 4.

### Claim 9 (depends on 1)

An acylethanolamide composition/porous amorphous silica adsorption compound, comprising the acylethanolamide composition of claim 1.

### Claim 10 (depends on 1)

A human or veterinary pharmaceutical formulation comprising the acylethanolamide composition according to claim 1 or an acylethanolamide composition/porous amorphous silica adsorption compound comprising the acylethanolamide composition, wherein the formulation is in dosage forms for oral, buccal, parenteral, rectal, or transdermal administration.

### Claim 11 (depends on 10)

The pharmaceutical formulation according to claim 10, wherein the acylethanolamide composition is contained in a liquid dosage form.

### Claim 12 (depends on 10)

The pharmaceutical formulation according to claim 10, wherein the acylethanolamide composition/porous amorphous silica adsorption compound is contained in a solid dosage form.

### Claim 13 (depends on 1, 9)

A dietary formulation, food supplement or food for special medical purposes (FSMP), comprising the acylethanolamide composition according to claim 1 or the an acylethanolamide composition/porous amorphous silica adsorption compound according to claim 9 comprising the acylethanolamide composition.

### Claim 14 (depends on 1)

A method for treating a low grade neuroinflammation comprising administering an effective amount of the acylethanolamide composition according to claim 1 or of the an acylethanolamide composition/porous amorphous silica adsorption compound comprising the acylethanolamide composition or a formulation comprising the acylethanolamide composition.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the method comprises treatment of a population of patients suffering from obesity.

### Claim 16 (depends on 4)

The method according to claim 4, wherein in step a) the weight ratio of olive oil/2-ethanolamine is between 100:15 and 100:20.

### Claim 17 (depends on 4)

The method according to claim 4, wherein in step a) the weight ratio of olive oil/2-ethanolamine is between 100:16 and 100:18.

### Claim 18 (depends on 4)

The method according to claim 4, wherein step b) is carried out at a temperature between 135° C. and 145° C., and for a time over 2 hours and less than 5 hours.

### Claim 19 (depends on 4)

The method according to claim 4, wherein step b) is carried out at a temperature between 130° C. and 150° C. for a time over 2 hours and less than 5 hours.

### Claim 20 (depends on 4)

The method according to claim 4, wherein step d) is carried out by melting the acylethanolamide composition of step c) at a temperature between 70° C. and 90° C. and then adding porous amorphous silica, and wherein the weight ratio of acylethanolamide composition to porous amorphous silica is about 1:1.
